Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline receives EU approval for Tafinlar

GlaxoSmithKline receives EU approval for Tafinlar

4th September 2013

GlaxoSmithKline has announced that the European Commission has approved its innovative new melanoma therapy Tafinlar.

The oral targeted treatment is indicated for use as a monotherapy for unresectable melanoma or metastatic melanoma in adult patients with a BRAF V600 mutation, with patients needing to take a test to confirm the presence of this mutation before they begin treatment.

It represents a promising new therapy option for the most serious and deadly form of skin cancer, with evidence from clinical trials showing the significant survival benefits it can provide.

GlaxoSmithKline has been able to bring this product to market within five years of commencing initial testing.

Dr Paolo Paoletti, president of GlaxoSmithKline Oncology, said: "With this new personalised medicine, we hope to make a meaningful difference in the lives of appropriate patients with metastatic melanoma."

This comes after the European Commission approved GlaxoSmithKline's drug Tyverb in a new indication for breast cancer last month.ADNFCR-8000103-ID-801633339-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.